SUBSCRIBE
SUBSCRIBE

Phase I

Drug Development
Biopharma Update on the Novel Coronavirus: July 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 1, 2020.
June 30, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: June 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.
June 29, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Drug Development
Clinical Catch-Up: June 22-26
It was a busy week for clinical trial updates. Here’s a look.
June 26, 2020
 · 
7 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: June 26
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
June 25, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: June 24
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
June 23, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: June 22
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
June 22, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Clinical Catch-Up: June 15-19
It was a busy week for clinical trial announcements. Here’s a look.
June 19, 2020
 · 
12 min read
 · 
Mark Terry
Drug Development
Clinical Trials Are Starting Back Up, but Some Future Approvals May be Delayed
According to a BioPharma Dive report, since March, more than 100 biopharma companies announced their clinical trials were disrupted in some way because of the pandemic.
June 19, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: June 19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
June 18, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Pfizer and Sangamo Release Updated Gene Therapy Data in Hemophilia A
Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.
June 18, 2020
 · 
3 min read
 · 
Alex Keown
Load More
PRESS RELEASES
Drug Development
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at ASCO 2024 Meeting
June 3, 2024
 · 
8 min read
Drug Development
Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting
June 3, 2024
 · 
5 min read
Drug Development
IDRx Reports Updated Preliminary Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial Supporting Best-in-Class Potential for IDRX-42 in Patients with GIST
June 3, 2024
 · 
8 min read
Drug Development
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
June 3, 2024
 · 
9 min read
Drug Development
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
June 3, 2024
 · 
7 min read
Drug Development
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
June 3, 2024
 · 
9 min read
Drug Development
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
June 2, 2024
 · 
17 min read
Drug Development
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
June 2, 2024
 · 
9 min read
Drug Development
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
June 2, 2024
 · 
11 min read
Drug Development
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
June 2, 2024
 · 
11 min read
Drug Development
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
June 1, 2024
 · 
9 min read
Drug Development
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
June 1, 2024
 · 
4 min read
Drug Development
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
June 1, 2024
 · 
9 min read
Drug Development
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
June 1, 2024
 · 
3 min read
Drug Development
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
June 1, 2024
 · 
8 min read
Drug Development
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
June 1, 2024
 · 
3 min read
Drug Development
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
June 1, 2024
 · 
9 min read
Drug Development
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 31, 2024
 · 
17 min read
Drug Development
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
May 31, 2024
 · 
10 min read
Drug Development
Avirmax Biopharma Inc. Receives IND Approval for Phase I/IIa Trial to Treat Wet AMD including PCV
May 30, 2024
 · 
2 min read
Load More